Special Issue

mTOR Signaling in Cancer Development and Growth

Message from the Guest Editor

Mechanistic target of rapamycin (mTOR) is a critical protein kinase that regulates cell growth, survival, and metabolism. It forms two distinct complexes—mTORC1 and mTORC2. Several known genetic mutations (PIK3CA, KRAS, BRAF, etc.) result in the activation of mTOR. The activation of mTOR has been shown to facilitate the growth and metastasis of various tumors through the promotion of anabolic processes (protein and lipid synthesis) and the inhibition of catabolic processes (autophagy). As such, many inhibitors of mTOR have been developed for cancer therapy. The scope of this Special Issue is to deepen our understanding of the roles of mTOR in cancer development and growth.

Guest Editor

Dr. Evie H. Carchman

1. Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
2. Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
3. William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705, USA

Deadline for manuscript submissions

closed (20 May 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/95008

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)